TIGIT and acute myeloid leukemia: A recent study that profiled the expression of specific immune cells and immune checkpoint markers in peripheral blood of 14 elderly AML patients treated with decitabine (pre- versus post-treatment, and in responders vs non-responders) suggested that combination of decitabine with novel ICB therapy such as anti-TIGIT antibodies might be a better therapeutic strategy than with conventional ICB regimens (anti-PD-1/L1 or -CTLA-4 antibodies) (101).